#India #Mumbai #Lupin Limited #ESMO Congress #LNP3693

Lupin to Unveil Phase 1 Data of LNP3693 at ESMO 2025

On October 13, 2025, Lupin Limited, a global leader in pharmaceuticals, announced that it will showcase data from its Phase 1 clinical trial on LNP3693, a novel STING agonist. This significant presentation will take place at the ESMO Congress, set to occur in Berlin, Germany from October 17 to 21, 2025. The details of this revelation have generated great anticipation within the medical and pharmaceutical communities as LNP3693 aims at addressing unmet needs in patients suffering from advanced solid tumors and lymphomas.

Key Event Presentation Details

The presentation is scheduled for October 19, 2025, from 09:00 to 17:00 CEST, and will be categorized under Immunotherapy in Research. The primary focus of the discussion will be the clinical trial titled "Phase 1 Dose Escalation Study of LNP3693 (STING Agonist) in Patients with Advanced Solid Tumors or Lymphoma," with registration number CTRI/2023/10/059147, and will bear the presentation number 1553P.

LNP3693 is seen as a promising investigational STING agonist designed for parenteral use. Lupin’s disclosure will not only highlight the safety and preliminary antitumor activities observed in participants but also provide insights into the pharmacokinetics and pharmacodynamics associated with the drug. The ongoing advancements in STING agonists, like LNP3693, are anticipated to foster greater understanding and development of innovative treatment methodologies in oncology.

Vision for Cancer Treatment

Vinita Gupta, CEO of Lupin, expressed enthusiasm for presenting the new data, reflecting on the recognition of the company's research efforts. "This is another significant milestone for us. Following the successful presentation of LNP7457, a PRMT5 inhibitor at ASCO in June 2025, it is an honor to share the findings of yet another Phase 1 clinical trial, this time with LNP3693 at ESMO. This acknowledgment emphasizes our team's capability in discovering, researching, and developing effective oncology drugs from India,” Gupta stated.

This presentation at ESMO 2025 reflects Lupin's commitment to advancing cancer therapy solutions and its ongoing contribution to the field through rigorous clinical research. The detailed analysis and discussion of the study outcomes are expected to open new avenues for treating cancer patients who may have limited alternatives.

ESMO 2025 and Future Implications

As part of a larger agenda for ESMO 2025, all accepted abstracts—including those relating to LNP3693—will be published online on the ESMO website. This publication will be accessible from October 13, enabling the wider global healthcare community to benefit from the latest research findings presented at the congress. The broader implications of LNP3693 and similar investigational therapies could reshape how oncologists approach treatment in the years to come.

With 15 state-of-the-art manufacturing facilities and 7 research centers around the globe, Lupin is poised to make significant strides towards improving patient outcomes. The commitment to enhancing healthcare through innovative cancer treatments remains at the core of Lupin’s mission.

For further inquiries about the presentation at ESMO 2025 or details about Lupin's extensive research portfolio, stakeholders can reach out through Lupin's media contacts provided earlier. With continued research and development, Lupin aims to enhance its versatility in delivering effective healthcare solutions globally.